Evidence map›Paper›PMID 41854362›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Albumin-Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8

Jinsong Tao, Hong-Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Kai Sun and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinsong TaoDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Hong-Yi ZhaoDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Chengyi LiDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Hanning WenDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Fang KeDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Qiuxia LiDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Miao HeDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Bo WenDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Zhongwei LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Kai SunDepartment of Materials Science and Engineering, College of Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Wei GaoDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-6406-2126

Funding

University of Michigan
6 · The paper itself

Abstract

Tumor-associated immunosuppressive neutrophils, termed polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), compromise cancer immunotherapy. Emerging evidence indicates that neutrophil fate can be programmed as early as the hematopoietic stem and progenitor cell (HSPC) stage. Reprogramming HSPCs toward antitumor neutrophils offers a promising therapeutic strategy. Here, we demonstrate that an albumin-bound STING agonist (Nano ZSA-51D) reprograms HSPCs to generate antitumor neutrophils, enhancing MHC I-mediated CD8

Indexed as

CD8-Positive T-LymphocytesHematopoietic Stem CellsMembrane ProteinsNeutrophilsAnimalscGAS-STING Signaling PathwayHumansImmunotherapyMiceMice, Inbred C57BLSTING ProteinMembrane ProteinsSting1 protein, mouseSTING Proteinantigen presentationantitumor neutrophilscancer immunotherapyCD8+ T cell immunityhematopoietic stem and progenitor cellsSTING agonist

Identifiers

PMID41854362
PMCPMC13205613

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.